

16 Spezielle Koronarinterventionen

16.1 Intervention an aortokoronaren Bypässen

- [1] Baim DS, Wahr D, George B et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. *Circulation* 105:1285–90, 2002
- [2] Bonello L, De Labriolle A, Lemesle G et al. Prognostic value of procedure-related myocardial infarction according to the universal definition of myocardial infarction in saphenous vein graft interventions. *Am Heart J* 157:894–8, 2009
- [3] Brennan JM, Al-Hejily W, Dai D et al. Three-year outcomes associated with embolic protection in saphenous vein graft intervention: results in 49 325 senior patients in the Medicare-linked National Cardiovascular Data Registry CathPCI Registry. *Circ Cardiovasc Interv* 8:e001403, 2015
- [4] Brilakis ES, Lichtenwalter C, de Lemos JA et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. *J Am Coll Cardiol* 53:919–28, 2009
- [5] Brilakis ES, O'Donnell CI, Penny W et al. Percutaneous coronary intervention in native coronary arteries versus bypass grafts in patients with prior coronary artery bypass graft surgery: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. *JACC Cardiovasc Interv* 9:884–93, 2016
- [6] Gaglia MA, Torguson R, Xue Z et al. Outcomes of patients with acute myocardial infarction from a saphenous vein graft culprit undergoing percutaneous coronary intervention. *Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv* 78:23–9, 2011
- [7] Gruberg L, Hellkamp AS, Thomas LE et al. The Association of Previous Revascularization with In-Hospital Outcomes in Acute Myocardial Infarction Patients: results from the National Cardiovascular Data Registry. *JACC Cardiovasc Interv* 8:1954–62, 2015
- [8] Halkin A, Masud AZ, Rogers C et al. Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. *Am Heart J* 151:915.e1–7, 2006
- [9] Hofmann M, Störger H, Schwarz F et al. Percutaneous saphenous vein graft interventions with and without distal filter wire protection. *J Intervent Cardiol* 18:475–9, 2005
- [10] Hong YJ, Pichard AD, Mintz GS et al. Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions. *Am J Cardiol* 105:179–85, 2010
- [11] Kohl LP, Garberich RF, Yang H et al. Outcomes of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction patients with previous coronary bypass surgery. *JACC Cardiovasc Interv* 7:981–7, 2014
- [12] Leborgne L, Cheneau E, Pichard A et al. Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. *Am Heart J* 146:501–6, 2003
- [13] Lee MS, Park S-J, Kandzari DE et al. Saphenous vein graft intervention. *JACC Cardiovasc Interv* 4:831–43, 2011
- [14] Leineweber K, Böse D, Vogelsang M et al. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. *J Am Coll Cardiol* 47:981–6, 2006
- [15] Mauri L, Cox D, Hermiller J et al. The PROXIMAL trial: proximal protection du-

ring saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. *J Am Coll Cardiol* 50:1442–9, 2007

- [16] Mehilli J, Pache J, Abdel-Wahab M et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. *Lancet Lond Engl* 378:1071–8, 2011
- [17] Mehta SK, Frutkin AD, Milford-Beland S et al. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19 546 patients in the American College of Cardiology – National Cardiovascular Data Registry). *Am J Cardiol* 100:1114–8, 2007
- [18] Rigattieri S, Sciahbasi A, Brilakis ES et al. Meta-analysis of radial versus femoral artery approach for coronary procedures in patients with previous coronary artery bypass grafting. *Am J Cardiol* 117:1248–55, 2016
- [19] Rodés-Cabau J, Bertrand OF, Larose E et al. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate non-significant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial. *Circulation* 120:1978–86, 2009
- [20] Stone GW, Rogers C, Hermiller J et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. *Circulation* 108:548–53, 2003
- [21] Welsh RC, Granger CB, Westerhout CM et al., APEX AMI Investigators (2010). Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. *JACC Cardiovasc Interv* 3:343–51, 2010

16.2 PCI koronarer Bifurkationsstenosen

- [1] Medina A, Suarez de Lezo J, Pan M. A new classification of coronary bifurcation lesions. *Rev Esp Cardiol* 59:183, 2006
- [2] Murray CD. The physiological principle of minimum work applied to the angle of branching of arteries. *J Gen Physiol* 9:835–41, 1926
- [3] Neumann FJ, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2018
- [4] Koo BK, Park KW, Kang HJ et al. Physiological evaluation of the provisional side-branch intervention strategy for bifurcation lesions using fractional flow reserve. *Eur Heart J* 29:726–32, 2008
- [5] Mintz GS, Lefèvre T, Lassen JF et al. Intravascular ultrasound in the evaluation and treatment of left main coronary artery disease: a consensus statement from the European Bifurcation Club. *EuroIntervention* 14:e467–74, 2018
- [6] Manabe O, Naya M, Aikawa T et al. PET/CT scanning with 3D acquisition is feasible for quantifying myocardial blood flow when diagnosing coronary artery disease. *EJNMMI Res* 7:52, 2017
- [7] Colombo A, Moses JW, Morice MC et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. *Circulation* 109:1244–9, 2004
- [8] Steigen TK, Maeng M, Wiseth R et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic Bifurcation Study. *Circulation* 114:1955–61, 2006
- [9] Ferenc M, Gick M, Kienzle RP et al. Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions. *Eur Heart J* 29:2859–67, 2008
- [10] Lassen JF, Burzotta F, Banning AP et al. Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club. *EuroIntervention* 13:1540–53, 2018
- [11] Colombo A, Bramucci E, Saccà S et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS

- (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. *Circulation* 119:71–8, 2009
- [12] Hildick-Smith D, de Belder AJ, Cooter N et al. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. *Circulation* 121:1235–43, 2010
- [13] Chen SL, Ye F, Zhang JJ et al. DK crush technique: modified treatment of bifurcation lesions in coronary artery. *Chin Med J* 118:1746–50, 2005
- [14] Chen SL, Santoso T, Zhang JJ et al. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial. *J Am Coll Cardiol* 57:914–20, 2011
- [15] Chen SL, Xu B, Han YL et al. Clinical outcome after DK Crush versus Culotte stenting of distal left main bifurcation lesions: the 3-year follow-up results of the DKCRUSH-III Study. *JACC Cardiovasc Interv* 8:1335–42, 2015
- [16] Chen SL, Zhang JJ, Han Y et al. Double Kissing Crush versus provisional stenting for left main distal bifurcation lesions: DKCRUSH-V randomized trial. *J Am Coll Cardiol* 70:2605–17, 2017
- [16a] Hildick-Smith D, Egred M, Banning A et al. The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN). *Eur Heart J* 42:3829–3839, 2021
- [16b] Tarantini G, Fovino LN, Varbella F et al. A large, prospective, multicentre study of left main PCI using a latest-generation zotarolimus-eluting stent: the ROLEX study. *EuroIntervention* 18:e1108–e1119, 2023
- [17] Ferenc M, Gick M, Comberg T et al. Culotte stenting vs. TAP stenting for treatment of de-novo coronary bifurcation lesions with the need for side-branch stenting: the Bifurcations Bad Krozingen (BBK) II angiographic trial. *Eur Heart J* 37:3399–405, 2016
- [18] Zhang JJ, Ye F, Xu K et al. Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial. *Eur Heart J* 41:2523–36, 2020
- [19] Ferenc M, Neumann FJ. Towards a lesion-specific approach to percutaneous coronary intervention for bifurcation lesions. *Eur Heart J* 41:2537–40, 2020
- [20] Lassen JF, Holm NR, Banning A et al. Percutaneous coronary intervention for coronary bifurcation disease: 11th consensus document from the European Bifurcation Club. *EuroIntervention* 2:38–46, 2016
- [21] Suzuki G, Nozaki Y, Sakurai M. A novel guidewire approach for handling acute-angle bifurcations: reversed guidewire technique with adjunctive use of a double-lumen microcatheter. *J Invasive Cardiol* 25:48–54, 2013
- [22] Pan M, Medina A, Romero M et al. Assessment of side branch predilation before a provisional T-stent strategy for bifurcation lesions. A randomized trial. *Am Heart J* 16:374–80, 2014
- [23] Hoyer A. The proximal optimisation technique for intervention of coronary bifurcations. *Interv Cardiol* 1:110–5, 2017
- [24] Niemelä M, Kervinen K, Erglis A et al. Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III. *Circulation* 123:79–86, 2011
- [25] Louvard Y, Medina A. Definitions and classifications of bifurcation lesions and treatment. *EuroIntervention* 11 Suppl V:V23–6, 2005
- [26] Toth GG, Sasi V, Franco D et al. Double-kissing Culotte technique for coronary bifurcation stenting – technical evaluation and comparison with conventional double stenting techniques. *EuroIntervention* 16:e724–33, 2020
- [27] Rab T, Sheiban I, Louvard Y et al. Current Interventions for the Left Main Bifurcation. *JACC Cardiovasc Interv* 10:849–865, 2017

16.3 PCI ostialer Läsionen

- [1] Pritchard CL, Mudd JG, Barner HB. Coronary ostial stenosis. *Circulation* 52:46–8, 1975

- [2] Yildirimturk O, Cansel M, Erdim R et al. Coexistence of left main and right coronary artery ostial stenosis: demographic and angiographic features. *Int J Angiol* 20:33–8, 2011
- [3] Wöhrle J, Markovic S. Percutaneous coronary interventions for ostial lesions. *Herz* 41:579–84, 2016
- [4] Neumann FJ, Sousa-Uva M, Ahlsson A et al., ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2019
- [5] Jokhi P, Curzen N. Percutaneous coronary intervention of ostial lesions. *EuroIntervention* 5:511–4, 2009
- [6] von Birgelen C, Hartmann M. Intravascular ultrasound assessment of coronary atherosclerosis and percutaneous interventions. *Minerva Cardioangiol* 52:391–406, 2004
- [7] Pesenti-Rossi D, Chouli M, Gharbi M et al. Coronary aorto-ostial stenosis analysed by multislice computed tomography: a new tool for percutaneous coronary intervention? *EuroIntervention* 6:717–21, 2011
- [8] Jaffe R, Halon DA, Shiran A et al. Percutaneous treatment of aorto-ostial coronary lesions: current challenges and future directions. *Int J Cardiol* 186:61–6, 2015
- [9] Hussain F, Kashour T, Rajaram M. Ostial RCA intervention: guiding catheter challenges and use of a buddy wire to perform focused-force angioplasty on a severely calcific ostial right coronary lesion. *J Invasive Cardiol* 18: E298–301, 2006
- [10] Palmer ND, Nair RK, Ramsdale DR. Treatment of calcified ostial disease by rotational atherectomy and adjunctive cutting balloon angioplasty prior to stent implantation. *Int J Cardiovasc Intervent* 6:134–6, 2004
- [11] Ko E, Natsuaki M, Toyofuku M et al. Sirolimus-eluting stent implantation for ostial right coronary artery lesions: five-year outcomes from the j-Cypher registry. *Cardiovasc Interv Ther* 29:200–8, 2014
- [12] Okabe T, Kawamura A, Maekawa Y et al. Can intravascular ultrasound guidance modify the efficacy of drug-eluting stent over bare-metal stent in an aorto-ostial lesion? *Cardiovasc Revasc Med* 12:105–10, 2011

16.4 PCI der In-Stent-Restenose (ISR)

- [1] Pleva L, Kukla P Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review. *J Geriatr Cardiol* 15:173–84, 2018
- [2] Giacoppo D, Gargiulo G, Aruta P et al. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. *BMJ* 351:h5392, 2015; Erratum in: *BMJ* 351:h6364, 2015
- [3] Her AY, Shin ES. Current management of in-stent restenosis. *Korean Circ J* 48:337–49, 2018
- [4] Yin RX, Yang DZ, Wu JZ. Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. *Theranostics* 4:175–200, 2014
- [5] Tepe G, Wendel HP, Khorchidi S et al. Thrombogenicity of various endovascular stent types: an in vitro evaluation. *J Vasc Interv Radiol* 13:1029–35, 2002
- [6] Hofma SH, van der Giessen WJ, van Dalen BM et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. *Eur Heart J* 27:166–70, 2006
- [7] Berliner JA, Navab M, Fogelman AM et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. *Circulation* 91:2488–96, 1995
- [8] Glagov S, Weisenberg E, Zarins CK et al. Compensatory enlargement of human atherosclerotic coronary arteries. *N Engl J Med* 316:1371–5, 1987
- [9] Dangas G, Fuster V. Management of restenosis after coronary intervention. *Am Heart J* 132:428–36, 1996
- [10] Welt FG, Rogers C. Inflammation and restenosis in the stent era. *Arterioscler Thromb Vasc Biol*, 22:1769–76, 2002
- [11] Farb A, Weber DK, Kolodgie FD et al. Morphological predictors of restenosis after coronary stenting in humans. *Circulation* 105:2974–80, 2002
- [12] Farb A, Kolodgie FD, Hwang JY et al. Extracellular matrix changes in stented human coronary arteries. *Circulation* 110:940–7, 2004
- [13] Riessen R, Wight TN, Pastore C et al. Distribution of hyaluronan during extracellular matrix remodeling in human resteno-

- tic arteries and balloon-injured rat carotid arteries. *Circulation* 93:1141–7, 1996
- [14] Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. *Circulation* 111:2257–73, 2005
 - [15] Pocock SJ, Lansky AJ, Mehran R et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. *J Am Coll Cardiol* 51:23–32, 2008
 - [16] Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. *Circulation* 111:3435–42, 2005
 - [17] Kasaoka S, Tobis JM, Akiyama T et al. Angiographic and intravascular ultrasound predictors of in-stent restenosis. *J Am Coll Cardiol* 32:1630–5, 1998
 - [18] Sonoda S, Morino Y, Ako J et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the SIRIUS trial. *J Am Coll Cardiol* 43:1959–63, 2004
 - [19] Gonzalo N, Serruys PW, Okamura T et al. Optical coherence tomography patterns of stent restenosis. *Am Heart J* 158:284–93, 2009
 - [20] Nef HM, Boeder NF, Abdel-Wahab M et al. Empfehlungen zur Anwendung von intravaskulärer Bildgebung (optische Kohärenztomographie). *Kardiologie* 11:8–15, 2017
 - [21] Andreini D, Pontone G, Mushtaq S et al. Coronary in-stent restenosis: assessment with CT coronary angiography. *Radiology* 265:410–7, 2012
 - [22] Sun Z, Davidson R, Lin CH. Multi-detector row CT angiography in the assessment of coronary in-stent restenosis: a systematic review. *Eur J Radiol* 69:489–95, 2009
 - [23] Sun Z, Almutairi AM. Diagnostic accuracy of 64 multislice CT angiography in the assessment of coronary in-stent restenosis: a meta-analysis. *Eur J Radiol* 73:266–73, 2010
 - [24] Kumbhani DJ, Ingelmo CP, Schoenhagen P et al. Meta-analysis of diagnostic efficacy of 64-slice computed tomography in the evaluation of coronary in-stent restenosis. *Am J Cardiol* 103:1675–81, 2009
 - [25] Bainey KR, Norris CM, Graham MM et al., APPROACH investigators. Clinical in-stent restenosis with bare metal stents: is it truly a benign phenomenon? *Int J Cardiol* 128:378–82, 2008
 - [26] Mehran R, Dangas G, Abizaid AS et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. *Circulation* 100:1872–8, 1999
 - [27] Alfonso F, Cequier A, Angel J et al. Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis. Insights from the Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) randomized trial. *Am Heart J* 151:681.e1–e9, 2006
 - [28] Petretta M, Acampa W, Daniele S et al. Long-term survival benefit of coronary revascularization in patients undergoing stress myocardial perfusion imaging. *Circ J* 80:485–93, 2016
 - [29] Baschet L, Bourguignon S, Marque S et al. Cost-effectiveness of drug-eluting stents versus bare-metal stents in patients undergoing percutaneous coronary intervention. *Open Heart* 3:e000445, 2016
 - [30] Köster R, Vieluf D, Kiehn M et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. *Lancet* 356:1895–7, 2000
 - [31] Moustapha A, Assali AR, Sdringola S et al. Abciximab administration and clinical outcomes after percutaneous intervention for in-stent restenosis. *Catheter Cardiovasc Interv* 56:184–7, 2002
 - [32] Kufner S, Hausleiter J, Ndrepepa G et al. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. *JACC Cardiovasc Interv* 2:1142–8, 2009
 - [33] Alfonso F, Pérez-Vizcayno MJ, Cruz A et al. Treatment of patients with in-stent restenosis. *EuroIntervention* 5(D):D70–8, 2009
 - [34] Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 35:2541–619, 2014

- [35] Alfonso F, Byrne RA, Rivero F et al. Current treatment of in-stent restenosis. *J Am Coll Cardiol* 63:2659–73, 2014
- [36] Alfonso F, Pérez-Vizcayno MJ, Gómez-Reico M et al. Implications of the „watermelon seeding“ phenomenon during coronary interventions for in-stent restenosis. *Catheter Cardiovasc Interv* 66:521–7, 2005
- [37] Byrne R, Neumann FJ, Mehilli J et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. *Lancet* 381:461–7, 2013
- [38] Adamian M, Colombo A, Briguori C et al. Cutting balloon angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty. *J Am Coll Cardiol* 38:672–9, 2001
- [39] Albiero R, Silber S, Di Mario C et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). *J Am Coll Cardiol* 43:943–9, 2004
- [40] Kufner S, Joner M, Schneider S et al. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: a randomized controlled trial. *JACC Cardiovasc Interv* 10:1332–40, 2017
- [41] Mehran R, Dangas G, Mintz GS et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. *Circulation* 101:2484–9, 2000
- [42] vom Dahl J, Dietz U, Haager PK et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). *Circulation* 105:583–8, 2002
- [43] Holmes DR Jr, Teirstein P, Satler L et al. Sirolimus-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISr randomized trial. *JAMA* 295:1264–73, 2006
- [44] Leon MB, Teirstein PS, Moses JW et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. *N Engl J Med* 344:250–46, 2001
- [45] Alfonso F, Zueco J, Cequier A et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. *J Am Coll Cardiol* 42:796–805, 2003
- [46] Kastrati A, Dibra A, Eberle S et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs. balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. *JAMA* 293:165–171, 2005
- [47] Alfonso F, Pérez-Vizcayno MJ, Hernández R et al. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. *J Am Coll Cardiol* 52:1621–7, 2008
- [48] Byrne RA, Cassese S, Windisch T et al. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. *EuroIntervention* 9:797–802, 2013
- [49] Alfonso F, Pérez-Vizcayno MJ, Dutary J et al. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). *JACC Cardiovasc Interv* 5:728–37, 2012
- [50] Jamshidi P, Nyffenegger T, Sabti Z et al. A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold. *EuroIntervention* 11:1479–86, 2016
- [51] Longo G, Granata F, Capodanno D et al. Anatomical features and management of bioresorbable vascular scaffolds failure: a case series from the GHOST registry. *Catheter Cardiovasc Interv* 85:1150–61, 2015
- [52] Scheller B, Hehrlein C, Bocks W et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. *N Engl J Med* 355:2113–24, 2006

- [53] Unverdorben M, Vallbracht C, Cremers B et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. *Circulation* 119:2986–94, 2009
- [54] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). *J Am Coll Cardiol* 63:1378–86, 2014
- [55] Habara S, Mitsudo K, Kadota K et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. *JACC Cardiovasc Interv* 4:149–54, 2011
- [56] Rittger H, Brachmann J, Sinha AM et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. *J Am Coll Cardiol* 59:1377–82, 2012
- [57] Xu B, Gao R, Wang J et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. *JACC Cardiovasc Interv* 7:204–11, 2014
- [58] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. *J Am Coll Cardiol* 66:23–33, 2015
- [59] Siontis GC, Stefanini GG, Mavridis D et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. *Lancet* 386:655–64, 2015
- [60] Latib A, Mussardo M, Ielasi A et al. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. *JACC Cardiovasc Interv* 4:155–64, 2011
- [61] Habara S, Iwabuchi M, Inoue N et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. *Am Heart J* 166:527–33, 2013
- [62] Chorny M, Fishbein I, Yellen BB et al. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. *Proc Natl Acad Sci* 107:8346–51, 2010
- [63] Imaizumi S, Miura S, Takata K et al. Association between cholesterol efflux capacity and coronary restenosis after successful stent implantation. *Heart Vessels* 31:1257–65, 2016
- [64] Stone GW, Ellis SG, O'Shaughnessy CD et al. Paclitaxel-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. *JAMA* 295:1253–63, 2006
- [65] Kawai K, Akahori H, Imanaka T et al. Coronary restenosis of in-stent protruding bump with rapid progression: optical frequency domain imaging and angioscopic observation. *J Cardiol Cases* 19:12–4, 2019
- [66] Alfonso F, Pérez-Vizcayno MJ, Hernandez R et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. *J Am Coll Cardiol* 47:2152–60, 2006
- [67] Scheller B, Hehrlein C, Bocks W et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. *Clin Res Cardiol* 97:773–81, 2008
- [68] Pleva L, Kukla P, Kusnierova P et al. Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimus-eluting stents in the treatment of coronary in-stent restenosis: the Treatment of in-stent Restenosis Study. *Circ Cardiovasc Interv* 9:e003316, 2016
- [69] Mehilli J, Byrne RA, Tiroch K et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. *J Am Coll Cardiol* 55:2710–6, 2010
- [70] Wöhrle J, Zadura M, Möbius-Winkler S et al. SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-

- scale, prospective registry study. *J Am Coll Cardiol* 60:1733–8, 2012
- [71] Stella PR, Belkacemi A, Waksman R et al. The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment. *EuroIntervention* 7:705–10, 2011
- [72] Loh J, Stella PR, Sangiorgi G et al. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial. *Cardiovasc Revasc Med* 15:23–8, 2014
- [73] Naganuma T, Latib A, Costopoulos C et al. Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. *EuroIntervention* 11:989–95, 2016
- [74] Hong SJ, Ahn CM, Kim BK et al. Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents: intravascular ultrasound volumetric analysis (RESTENT-ISR trial). *Eur Heart J* 37:3409–18, 2016
- [75] Nijhoff F, Stella PR, Troost MS et al. Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis. *Clin Res Cardiol* 105:401–11, 2016
- [76] Pleva L, Kukla P, Zapletalova J et al. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. *BMC Cardiovasc Disord* 17:168, 2017
- [77] Assadi-Schmidt A, Mohring A, Liebsch E et al. SeQuent Please vs. Pantera Lux drug coated balloon angioplasty in real life: Results from the Dusseldorf DCB registry. *Int J Cardiol* 231:68–72, 2017
- [78] Masuda S, Nakano K, Funakoshi K et al. Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. *J Atheroscler Thromb* 18:1043–53, 2011
- [79] Bhargava B, Reddy NK, Karthikeyan G et al. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, non-polymeric cobalt-chromium stent: evaluation in a porcine model. *Catheter Cardiovasc Interv* 67:698–702, 2006
- [80] Tsukie N, Nakano K, Matoba T et al. Pita-vastatin-incorporated nanoparticle-eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model. *J Atheroscler Thromb* 20:32–45, 2013
- [81] Acharya G, Lee CH, Lee Y. Optimization of cardiovascular stent against restenosis: factorial design-based statistical analysis of polymer coating conditions. *PLoS One* 7:e43100, 2012

16.5 Rotations- und orbitale (Kreisel-)Atherektomie

- [1] Schlumpf M. 30 Jahre Ballonkatheter: Andreas Grüntzig, ein Pionier in Zürich. *Schweiz Ärztezeitung* 85:346–51, 2004
- [2] Hansen DD, Auth DC, Vracko R et al. Rotational atherectomy in atherosclerotic rabbit iliac arteries. *Am Heart J* 115(1 Pt 1):160–5, 1988
- [3] Hansen DD, Auth DC, Hall M et al. Rotational endarterectomy in normal canine coronary arteries: preliminary report. *J Am Coll Cardiol* 11:1073–7, 1988
- [4] Ahn SS, Auth D, Marcus DR et al. Removal of focal atheromatous lesions by angioscopically guided high-speed rotary atherectomy. Preliminary experimental observations. *J Vasc Surg* 7:292–300, 1988
- [5] Kaltenbach M, Vallbracht C, Hartmann A. Recanalization of chronic coronary occlusions by low speed rotational angioplasty (ROTACS). *J Interv Cardiol* 4:155–65, 1991
- [6] Barbato E, Shlofmitz E, Milkas A et al. State of the art: evolving concepts in the treatment of heavily calcified and undilatable coronary stenoses – from debulking to plaque modification, a 40-year-long journey. *EuroIntervention* 13:696–705, 2015
- [6a] Rocha-Singh KJ, Sachar R, DeRubertis BG et al. Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: the VIVA REALITY study. *Catheter Cardiovasc Interv* 98:549–58, 2021
- [6b] Wei L, Guo J, Guo L et al. Directional atherectomy and drug-coated balloon an-

- gioplasty vs. bare nitinol stent angioplasty for femoropopliteal artery lesions. *Vasa* 51: 275–81, 2022
- [7] Kini A, Marmur JD, Duvvuri S et al. Rotational atherectomy: improved procedural outcome with evolution of technique and equipment. Single-center results of first 1000 patients. *Catheter Cardiovasc Interv* 46:305–11, 1999
 - [8] Heuser RR. Treatment of lower extremity vascular disease: the Diamondback 360 degrees Orbital Atherectomy System. *Expert Rev Med Devices* 5:279–86, 2008
 - [9] Adams GL, Khanna PK, Staniloae CS et al. Optimal techniques with the Diamondback 360° System achieve effective results for the treatment of peripheral arterial disease. *J Cardiovasc Transl Res* 4:220–9, 2011
 - [10] Sotomi Y, Shlofmitz RA, Colombo A et al. Patient selection and procedural considerations for coronary orbital atherectomy system. *Interv Cardiol* 11:33–8, 2016
 - [11] Matsuo H, Watanabe S, Watanabe T et al. Prevention of no-reflow-/slow-flow phenomenon during rotational atherectomy – a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil. *Am Heart J* 154:994.e1–6, 2007
 - [12] Sharma SK, Tomey MI, Teirstein PS et al. North American expert review of rotational atherectomy. *Circ Cardiovasc Interv* 12:e007448, 2019
 - [13] Barbato E, Carrié D, Dardas P et al. European expert consensus on rotational atherectomy. *EuroIntervention*. 11:30–6, 2015
 - [14] Whitlow PL, Bass TA, Kipperman RM et al. Results of the study to determine rotablator and transluminal angioplasty strategy (STRATAS). *Am J Cardiol* 87:699–705, 2001
 - [15] Safian RD, Feldman T, Muller DW et al. Coronary Angioplasty and Rotablator Atherectomy Trial (CARAT): immediate and late results of a prospective multicenter randomized trial. *Catheter Cardiovasc Interv* 53:213–20, 2001
 - [16] <https://www.bostonscientific.com/en-US/products/atherectomy-systems/rotational-atherectomy-systems/rotapro.html> (21.12.21)
 - [17] Lee MS, Kim MH, Rha SW. Alternative rota-flush solution for patients with severe coronary artery calcification who undergo rotational atherectomy. *J Invasive Cardiol* 29:25–8, 2017
 - [18] Gurm HS, Breitbart Y, Vivekanathan D et al. Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy – a propensity-adjusted analysis. *Am Heart J* 151:1031, 2006
 - [19] Williams MS, Collier BS, Väänänen HJ et al. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro). *Circulation* 98:742–8, 1998
 - [20] Bau J, Gutensohn K, Kuck KH et al. Flow-cytometric analysis of platelet activation during rotablation. *Z Kardiol* 89:15–20, 2000
 - [21] Gurm HS, Breitbart Y, Vivekanathan D et al. Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy – a propensity-adjusted analysis. *Am Heart J* 151:1031, 2006
 - [22] Shlofmitz E, Martinsen BJ, Lee M et al. Orbital atherectomy for the treatment of severely calcified coronary lesions: evidence, technique, and best practices. *Expert Rev Med Devices* 14:867–79, 2017
 - [23] Egred M, Andron M, Alahmar A et al. High-speed rotational atherectomy during transradial percutaneous coronary intervention. *J Invasive Cardiol* 20:219–21, 2008
 - [24] You W, Wu X-Q, Ye F et al. Advantages of transradial rotational atherectomy versus transfemoral approach in elderly patients with hard-handling calcified coronary lesions – a single center experience. *Acta Cardiol Sin* 34:464–71, 2018
 - [24] Desai R, Mirza O, Martinsen BJ et al. Plaque modification of severely calcified coronary lesions via orbital atherectomy: single-center observations from a complex Veterans Affairs cohort. *Health Sci Rep* 1:e99, 2018
 - [25] Tanigawa J, Barlis P, Di Mario C. Heavily calcified coronary lesions preclude strut apposition despite high pressure balloon dilatation and rotational atherectomy: in-vivo demonstration with optical coherence tomography. *Circ J* 72:157–60, 2008
 - [26] Jiménez-Valero S, Galeote G, Sánchez-Recalde A et al. Optical coherence tomogra-

- phy after rotational atherectomy. *Rev Esp Cardiol* 62:585–6, 2009
- [27] Tsuchikane E, Suzuki T, Asakura Y et al. Debulking of chronic coronary total occlusions with rotational or directional atherectomy before stenting: Final results of DOCTORS study. *Int J Cardiol* 125:397–403, 2008
- [28] Abdel-Wahab M, Toelg R, Byrne RA et al. High-Speed rotational atherectomy versus modified balloons prior to drug-eluting stent implantation in severely calcified coronary lesions. *Circ Cardiovasc Interv* 11:e007415, 2018, Erratum in: *Circ Cardiovasc Interv* 11:e000040, 2018
- [29] Amemiya K, Yamamoto MH, Maehara A et al. Effect of cutting balloon after rotational atherectomy in severely calcified coronary artery lesions as assessed by optical coherence tomography. *Catheter Cardiovasc Interv* 94:936–44, 2019
- [30] Erbel R, O'Neill W, Auth D et al. High-frequency rotablation of occluded coronary artery during heart catheterization. *Cathet Cardiovasc Diagn* 17:56–8, 1989
- [31] Erbel R, O'Neill W, Auth D et al. High-frequency rotational atherectomy in coronary heart disease. *Dtsch Med Wochenschr* 114:487–95, 1989
- [32] Mohr-Kahaly S, Erbel R, Zotz R et al. Left ventricular contrast echocardiography using Gelifundo – assessment of hemodynamics, contractility and ECG. *Z Kardiol* 76:699–705, 1987
- [33] Zotz R, Stähr P, Erbel R et al. Analysis of high-frequency rotational angioplasty-induced echo contrast. *Cathet Cardiovasc Diagn* 22:137–44, 1991
- [34] Zotz RJ, Erbel R, Philipp A et al. High-speed rotational angioplasty-induced echo contrast in vivo and in vitro optical analysis. *Cathet Cardiovasc Diagn* 26:98–109, 1992
- [35] Kume T, Okura H, Kawamoto T et al. Assessment of the histological characteristics of coronary arterial plaque with severe calcification. *Circ J* 71:643–7, 2007
- [36] Chambers JW, Feldman RL, Himmelstein SI et al. Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calcified coronary lesions (ORBIT II). *JACC Cardiovasc Interv* 7:510–8, 2014
- [37] Haude M, Caspari G, Baumgart D et al. Comparison of myocardial perfusion reserve before and after coronary balloon predilatation and after stent implantation in patients with postangioplasty restenosis. *Circulation* 94:286–97, 1996
- [38] van Liebergen RA, Piek JJ, Koch KT et al. Immediate and long-term effect of balloon angioplasty or stent implantation on the absolute and relative coronary blood flow velocity reserve. *Circulation* 98:2133–40, 1998
- [39] Bowers TR, Stewart RE, O'Neill WW et al. Effect of rotablator atherectomy and adjunctive balloon angioplasty on coronary blood flow. *Circulation* 95:1157–64, 1997
- [40] Tanaka T, Shimizu Y, Ishihara A et al. Effect of rotational atherectomy on the coronary microcirculation in patients with angina pectoris. *J Cardiol* 46:43–51, 2005
- [41] Hori M, Inoue M, Kitakaze M et al. Role of adenosine in hyperemic response of coronary blood flow in microembolization. *Am J Physiol* 250(3 Pt 2):H509–18, 1986
- [42] Dietz U, Erbel R, Rupprecht HJ et al. High-frequency rotational ablation following failed percutaneous transluminal coronary angioplasty. *Cathet Cardiovasc Diagn* 31:179–86, 1994
- [43] Haude M, Eick B, Baumgart D et al. High frequency rotational angioplasty. *Z Kardiol* 85 (Suppl 1):17–23, 1996
- [44] Shlofmitz E, Chambers J, Moses JW et al. TCT-389 temporary pacemaker placement incidence with the Diamondback 360® Coronary Orbital Atherectomy System compared to rotational atherectomy. *Am Coll Cardiol* 66(15, Suppl):B157, 2015
- [45] Chambers JW, Diage T. Evaluation of the Diamondback 360 Coronary Orbital Atherectomy System for treating de novo, severely calcified lesions. *Expert Rev Med Devices* 11:457–66, 2014
- [46] Eggebrecht H, Ritzel A, von Birgelen C et al. Acute and long-term outcome after coronary artery perforation during percutaneous coronary interventions. *Z Kardiol* 93:791–8, 2004
- [47] Tomey MI, Kini AS, Sharma SK. Current status of rotational atherectomy. *JACC Cardiovasc Interv* 7:345–53, 2014
- [48] Shimony A, Joseph L, Mottillo S et al. Coronary artery perforation during percutaneous coronary intervention: a systematic review and meta-analysis. *Can J Cardiol* 27:843–50, 2011

- [49] Kiernan T, Yan BP, Rosenfield K et al. Coil embolization of an iatrogenic coronary artery to cardiac vein fistula after rotational atherectomy. *J Interv Cardiol* 21:410–3, 2008
- [50] Kaul U, Singh B, Vijan V et al. Rotablation-included coronary perforation during management of in-stent restenosis. *Indian Heart J* 50:203–5, 1998
- [51] Dietz U, Rupprecht HJ, Ekinici O et al. Angiographic analysis of immediate and long-term results of PTCR vs. PTCA in complex lesions (COBRA study). *Catheter Cardiovasc Interv* 53:359–367, 2001
- [52] Whitlow PL, Bass TA, Kipperman RM et al. Results of the study to determine rotablator and transluminal angioplasty strategy (STRATAS). *Am J Cardiol* 87:699–705, 2001
- [53] Safian RD, Feldman T, Muller DW et al. Coronary Angioplasty and Rotablator Atherectomy Trial (CARAT): immediate and late results of a prospective multicenter randomized trial. *Catheter Cardiovasc Interv* 53:213–20, 2001
- [54] Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 35:2541–619, 2014
- [55] Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol* 58:e44–122, 2011
- [56] Koller PT, Mooney MR. Rotablation and stent placement in an unprotected left main coronary ostial stenosis. *J Interv Cardiol* 8:633–8, 1995
- [57] Sperling RT, Ho K, James D et al. Treatment of stent-jailed side branch stenosis with rotational atherectomy. *J Invasive Cardiol* 18:354–8, 2006
- [58] Dill T, Dietz U, Hamm CW et al. A randomized comparison of balloon angioplasty versus rotational atherectomy in complex coronary lesions (COBRA study). *Eur Heart J* 21:1759–66, 2000
- [59] Mangiacapra F, Heyndrickx GR, Puymirat E et al. Comparison of drug-eluting versus bare-metal stents after rotational atherectomy for the treatment of calcified coronary lesions. *Int J Cardiol* 154:373–6, 2012
- [60] de Waha S, Allali A, Büttner HJ et al. Rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: Two-year clinical outcome of the randomized ROTAXUS trial. *Catheter Cardiovasc Interv* 87:691–700, 2016
- [61] Dobrzycki S, Reczuch K, Legutko J et al. Rotational atherectomy in everyday clinical practice. Association of Cardiovascular Interventions of the Polish Society of Cardiology (Asocjacja Interwencji Sercowo-Naczyniowych Polskiego Towarzystwa Kardiologicznego – AISN PTK): Expert opinion. *Kardiol Pol* 76:1576–84, 2018
- [61a] Redfors B, Sharma SK, Saito S et al. Novel micro crown orbital atherectomy for severe lesion calcification: Coronary Orbital Atherectomy System Study (COAST). *Circ Cardiovasc Interv* 13(8):e008993, 2020
- [61b] Lee M, G  n  reux P, Shlofmitz R et al. Orbital atherectomy for treating de novo, severely calcified coronary lesions: 3-year results of the pivotal ORBIT II trial. *Cardiovasc Revasc Med* 18:261–4, 2017
- [61c] Martinsen BJ, Kumar K, Saito S et al. USA orbital atherectomy for calcific coronary lesions: COAST Study, harmonization by doing proof-of-concept. *Cardiovasc Revasc Med* 7:112–7, 2022
- [62] Parikh K, Chandra P, Choksi N et al. Safety and feasibility of orbital atherectomy for the treatment of calcified coronary lesions: the ORBIT I trial. *Catheter Cardiovasc Interv* 81:1134–9, 2013
- [63] Bhatt P, Parikh P, Patel A et al. Long-term safety and performance of the orbital atherectomy system for treating calcified coronary artery lesions: 5-Year follow-up in the ORBIT I trial. *Cardiovasc Revasc Med* 16:213–6, 2015
- [64] Chambers JW, Feldman RL, Himmelstein SI et al. Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calci-

- fied coronary lesions (ORBIT II). JACC Cardiovasc Interv 7:510–8, 2014
- [64a] Lee M, Shlofmitz RA, Shlofmitz E et al. Orbital atherectomy for the treatment of small (2,5 mm) severely calcified coronary lesions: ORBIT II sub-analysis. Cardiovasc Revasc Med 19:268–72, 2018
- [65] Iwamoto S, Ohashi M, Shirato H et al. Japan-USA orbital atherectomy for calcific coronary lesions: COAST Study, a harmonization by doing proof-of-concept: the japanese and us regulatory perspective. Cardiovasc Revasc Med 37:118–9, 2022
- [66] Génèreux P, Kirtane AJ, Kandzari DE et al. Randomized evaluation of vessel preparation with orbital atherectomy prior to drug-eluting stent implantation in severely calcified coronary artery lesions: design and rationale of the ECLIPSE trial. Am Heart J 249:1–11, 2022
- [67] Lawton JS, Tamis-Holland JE, Bangalore S et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145: e18–e114, 2022
- Hybrid Procedures). JACC Cardiovasc Interv 10:1523–34, 2017
- [4] Wilson WM, Walsh SJ, Yan AT et al. Hybrid approach improves success of chronic total occlusion angioplasty. Heart 102:1486–93, 2016
- [5] Maeremans J, Walsh S, Knaapen P et al. The hybrid algorithm for treating chronic total occlusions in europe: the RE-CHARGE Registry. J Am Coll Cardiol 68:1958–70, 2016
- [6] Harding SA, Wu EB, Lo S et al. A new algorithm for crossing chronic total occlusions from the Asia Pacific Chronic Total Occlusion Club. JACC Cardiovasc Interv 10:2135–43, 2017
- [7] Galassi AR, Werner GS, Boukhris M et al. Percutaneous recanalisation of chronic total occlusions: 2019 consensus document from the EuroCTO Club. EuroIntervention 15:198–208, 2019
- [8] Goleski PJ, Nakamura K, Liebeskind E et al. Revascularization of coronary chronic total occlusions with subintimal tracking and reentry followed by deferred stenting: experience from a high-volume referral center. Catheter Cardiovasc Interv 93:191–8, 2019
- [9] Brilakis ES, Mashayekhi K, Tsuchikane E et al. Guiding principles for chronic total occlusion percutaneous coronary intervention. Circulation 140:420–33, 2019
- [10] Ge J, on behalf of Chronic Total Occlusion Club China. Strategic roadmap of percutaneous coronary intervention for chronic total occlusions [J]. Cardiol plus 3:30–7, 2018
- [11] Ge J, Ge L, Zhang B et al., on behalf of Chronic Total Occlusion Club China. Active greeting technique: a mother-and-child catheter based technique to facilitate retrograde wire externalization in recanalization of coronary chronic total occlusion. Sci Bull 63:1565–9, 2019
- [12] Tajti P, Burke MN, Karpaliotis D et al. Update in the percutaneous management of coronary chronic total occlusions. JACC Cardiovasc Interv 11:615–25, 2018
- [13] Ge J, Ge L, Huo Y et al. Updated algorithm of chronic total occlusion percutaneous coronary intervention from chronic total occlusion club China. Cardiology Plus 6:81–87, 2021
- [1] Galassi AR, Brilakis ES, Boukhris M et al. Appropriateness of percutaneous revascularization of coronary chronic total occlusions: an overview. Eur Heart J 37:2692–700, 2016
- [1a] Mashayekhi K, Bufe A, Werner GS et al. Behandlung von chronischen Koronarverschlüssen (CTO). Positionspapier der Deutschen Gesellschaft für Kardiologie. Kardiologie 15:320–40, 2021
- [2] Brilakis ES, Grantham JA, Rinfret S et al. A percutaneous treatment algorithm for crossing coronary chronic total occlusions. JACC Cardiovasc Interv 5:367–79, 2012
- [3] Sapontis J, Salisbury AC, Yeh RW et al. Early procedural and health status outcomes after chronic total occlusion angioplasty: a report from the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion

16.6 PCI bei chronischen Verschlüssen der Koronararterien

16.7 PCI bei Hauptstammstenosen

- [1] Angelini P. Coronary artery anomalies: an entity in search of an identity. *Circulation* 115(10):1296–305; 2007
- [2] El-Menyar AA, Al Suwaidi J, Holmes DR Jr. Left main coronary artery stenosis: state-of-the-art. *Curr Probl Cardiol* 32(3):103–93; 2007
- [3] Medrano-Gracia P, Ormiston J, Webster M et al. A computational atlas of normal coronary artery anatomy. *EuroIntervention* 12(7):845–54; 2016
- [4] Kim HY, Doh JH, Lim HS et al. Identification of coronary artery side branch supplying myocardial mass that may benefit from revascularization. *JACC Cardiovasc Interv* 10(6):571–81; 2017
- [5] Giannoglou GD, Antoniadis AP, Chatzizisis YS et al. Prevalence of narrowing $\geq 50\%$ of the left main coronary artery among 17 300 patients having coronary angiography. *Am J Cardiol* 98(9):1202–05, 2006
- [6] Khan MF, Athappan G. Left main coronary artery disease. *Interv Cardiol* 1:73–91, 2009
- [7] Predescu LM, Zarma L, Platon P et al. Current treatment of left main coronary artery disease. *Cor et Vasa* 58:e328–39, 2016
- [8] Oviedo C, Maehara A, Mintz GS et al. Intravascular ultrasound classification of plaque distribution in left main coronary artery bifurcations: where is the plaque really located? *Circ Cardiovasc Interv* 3(2):105–12, 2010
- [9] Neumann FJ, Sousa-Uva M, Ahlsson A et al., ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 40:87–165, 2019
- [10] Zhou Y, Kassab GS, Molloy S. On the design of the coronary arterial tree: a generalization of Murray's law. *Phys Med Biol* 44(12):2929–45, 1999
- [11] Mintz GS, Lefèvre T, Lassen JF et al. Intravascular ultrasound in the evaluation and treatment of left main coronary artery disease: a consensus statement from the European Bifurcation Club. *EuroIntervention* 14(4):e467–74, 2018
- [12] de la Torre Hernandez JM, Hernández Hernández F, Alfonso F et al. LITRO Study Group (Spanish Working Group on Interventional Cardiology). Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions results from the multicenter LITRO study. *J Am Coll Cardiol* 58(4):351–8, 2011
- [13] Dato I, Burzotta F, Trani C et al. Optical coherence tomography guidance for the management of angiographically intermediate left main bifurcation lesions: Early clinical experience. *Int J Cardiol* 248:108–13, 2017
- [14] Modi BN, van de Hoef TP, Piek JJ et al. Physiological assessment of left main coronary artery disease. *EuroIntervention* 13(7):820–7, 2017
- [15] Lassen JF, Burzotta F, Banning AP et al. Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club. *EuroIntervention* 13(13):1540–53, 2018
- [16] Burzotta F, Lassen JF, Banning AP et al. Percutaneous coronary intervention in left main coronary artery disease: the 13th consensus document from the European Bifurcation Club. *EuroIntervention* 14(1):112–20, 2018
- [17] Park SJ, Kim YH, Lee BK et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. *J Am Coll Cardiol* 45:351–6, 2005
- [18] Chieffo A, Hildick-Smith D. The European Bifurcation Club Left Main Study (EBC MAIN): rationale and design of an international, multicentre, randomised comparison of two stent strategies for the treatment of left main coronary bifurcation disease. *EuroIntervention* 12(1):47–52, 2016
- [19] Nam CW, Hur SH, Koo BK et al. Fractional flow reserve versus angiography in left circumflex ostial intervention after left main crossover stenting. *Korean Circ J* 41(6):304–7, 2011
- [20] Park SJ, Kim YH, Park DW et al., MAIN-COMPARE Investigators. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. *Circ Cardiovasc Interv* 2(3):167–77, 2009
- [21] Stone GW, Sabik JF, Serruys PW et al., EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main

- coronary artery disease. *N Engl J Med* 375(23):2223–35, 2016
- [22] Mäkilä T, Holm NR, Lindsay M et al., NOBLE study investigators. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. *Lancet* 388(10061):2743–52, 2016
- [23] Giacoppo D, Collieran R, Cassese S et al. Percutaneous coronary intervention vs. coronary artery bypass grafting in patients with left main coronary artery stenosis: a systematic review and meta-analysis. *JAMA Cardiol* 2(10):1079–88, 2017
- [5] Barath P, Fishbein MC, Vari S et al. Cutting balloon: a novel approach to percutaneous angioplasty. *Am J Cardiol* 68:1249–52, 1991
- [6] Okura H, Hayase M, Shimodono S et al. Mechanisms of acute lumen gain following cutting balloon angioplasty in calcified and noncalcified lesions: an intravascular ultrasound study. *Catheter Cardiovasc Interv* 57:429–36, 2002
- [7] Abdel-Wahab M, Toelg R, Byrne RA et al. High-speed rotational atherectomy versus modified balloons prior to drug-eluting stent implantation in severely calcified coronary lesions. *Circ Cardiovasc Interv* 11(10):e007415, 2018. Erratum in: *Circ Cardiovasc Interv* 11(10):e000040, 2018
- [8] Furuichi S, Tobaru T, Asano R et al. Rotational atherectomy followed by cutting-balloon plaque modification for drug-eluting stent implantation in calcified coronary lesions. *J Invasive Cardiol* 24:191–5, 2012
- [9] Kume T, Okura H, Kawamoto T et al. Assessment of the coronary calcification by optical coherence tomography. *EuroIntervention* 6:768–72, 2011
- [10] Kubo T, Shimamura K, Ino Y et al. Superficial calcium fracture after PCI as assessed by OCT. *JACC Cardiovasc Imaging* 8:1228–9, 2015
- [11] Maejima N, Hibi K, Saka K et al. Relationship between thickness of calcium on optical coherence tomography and crack formation after balloon dilatation in calcified plaque requiring rotational atherectomy. *Circ J* 80:1413–9, 2016
- [12] Amemiya K, Yamamoto MH, Maehara A et al. Effect of cutting balloon after rotational atherectomy in severely calcified coronary artery lesions as assessed by optical coherence tomography. *Catheter Cardiovasc Interv* 94:936–44, 2019
- [13] Ai H, Wang X, Suo M et al. Acute- and long-term outcomes of rotational atherectomy followed by cutting balloon versus plain balloon before drug-eluting stent implantation for calcified coronary lesions. *Chin Med J (Engl)* 131:2025–31, 2018
- [13a] Li Q, He Y, Chen L et al. Intensive plaque modification with rotational atherectomy and cutting balloon before drug-eluting stent implantation for patients with severely calcified coronary lesions:

16.8 PCI bei verkalkten Stenosen

- [1] Génereux P, Madhavan MV, Mintz GS et al. Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. *J Am Coll Cardiol* 63:1845–54, 2014
- [2] Bourantas CV, Zhang YJ, Garg S et al. Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. *Heart* 100:1158–64, 2014
- [3] Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 35:2541–619, 2014
- [4] Barbato E, Shlofmitz E, Milkas A et al. State of the art: evolving concepts in the treatment of heavily calcified and undilatable coronary stenoses – from debulking to plaque modification, a 40-year-long journey. *EuroIntervention* 13:696–705, 2017

- a pilot clinical study. *BMC Cardiovasc Disord* 16:112, 2016
- [14] de Ribamar Costa J Jr, Mintz GS, Carlier SG et al. Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. *Am J Cardiol* 100:812–7, 2007
- [15] Fonseca A, de Ribamar Costa J Jr, Abizaid A et al. Intravascular ultrasound assessment of the novel AngioSculpt scoring balloon catheter for the treatment of complex coronary lesions. *J Invasive Cardiol* 20:21–7, 2008
- [16] Mori S, Otsuka Y, Kawamura A. Usefulness of the SafeCut Dual Wire PTCA catheter for the treatment of calcified lesions. *Invasive Cardiol* 19:E254–6, 2007
- [17] Takano M, Yamamoto M, Murakami D et al. Optical coherence tomography after new scoring balloon angioplasty for in-stent restenosis and de novo coronary lesions. *Int J Cardiol* 141:e51–3, 2010
- [18] Otsuka Y, Koyama T, Imoto Y et al. Prolonged inflation technique using a scoring balloon for severe calcified lesion. *Int Heart J* 58:982–7, 2017
- [19] Erbel R, Schreiner G, Henkel B et al. Improved ischemic tolerance during percutaneous transluminal coronary angioplasty by intracoronary injection of nitroglycerin. *Z Kardiol* 72 Suppl 3:71–3, 1983
- [20] Erbel R, Hüttemann M, Schreiner G et al. Ischämietoleranz des Herzens bei der percutanen transluminalen koronaren Angioplastie. Kontrollierte Studie zum Effekt von Isosorbit-Dinitrat und Nifedipin. *Herz* 12:302–11, 1987
- [21] Busch U, Erbel R, Clas W et al. Verbesserte Ischämietoleranz mit Hilfe eines kontinuierlichen Perfusionskatheters, eines modifizierten Grüntzig-Angioplastiekatheters. *Z Kardiol* 74:435–9, 1985
- [22] Kawase Y, Saito N, Watanabe S et al. Utility of a scoring balloon for a severely calcified lesion: bench test and finite element analysis. *Cardiovasc Interv Ther* 29:134–9, 2014
- [23] Secco GG, Ghione M, Mattesini A et al. Very high-pressure dilatation for undilatable coronary lesions: indications and results with a new dedicated balloon. *Euro-Intervention* 12:359–65, 2016
- [24] Mintz GS, Kovach JA, Javier SP et al. Mechanisms of lumen enlargement after excimer laser coronary angioplasty. An intravascular ultrasound study. *Circulation* 92:3408–14, 1995
- [25] Redfors B, Maehara A, Witzenbichler B et al. Outcomes after successful percutaneous coronary intervention of calcified lesions using rotational atherectomy, cutting-balloon angioplasty, or balloon-only angioplasty before drug-eluting stent implantation. *J Invasive Cardiol* 29:378–86, 2017
- [26] Venuti G, D'Agosta G, Tamburino C et al. Coronary lithotripsy for failed rotational atherectomy, cutting balloon, scoring balloon, and ultra-high-pressure non-compliant balloon. *Catheter Cardiovasc Interv* 94:E111–5, 2019
- [27] Brinton TJ, Ali ZA, Hill JM et al. Feasibility of shockwave coronary intravascular lithotripsy for the treatment of calcified coronary stenoses. *Circulation* 139:834–6, 2019
- [28] Kawamoto H, Latib A, Ruparelina N et al. Planned versus provisional rotational atherectomy for severe calcified coronary lesions: insights from the ROTATE multicenter registry. *Catheter Cardiovasc Interv* 88:881–9, 2016
- [29] Wong B, El-Jack S, Newcombe R et al. Shockwave intravascular lithotripsy for calcified coronary lesions: first real-world experience. *J Invasive Cardiol* 31:46–8, 2019
- [30] Watkins S, Good R, Hill J et al. Intravascular lithotripsy to treat a severely underexpanded coronary stent. *EuroIntervention* 15:124–5, 2019
- [31] Sgueglia GA, Gioffrè G, Piccioni F et al. Slender distal radial five French coronary shockwave lithotripsy. *Catheter Cardiovasc Interv* 94:395–8, 2019
- [32] López-Lluya MT, Jurado-Román A, Sánchez-Pérez I et al. Shockwave: useful but potentially dangerous. *JACC Cardiovasc Interv* 12:500–1, 2019
- [33] Matsukawa R, Kozai T, Tokutome M et al. Plaque modification using a cutting balloon is more effective for stenting of heavily calcified lesion than other scoring balloons. *Cardiovasc Interv Ther* 34:325–34, 2019